SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 98.37 |
| Enterprise Value ($M) | -20.79 |
| Book Value ($M) | 114.29 |
| Book Value / Share | 4.23 |
| Price / Book | 0.86 |
| NCAV ($M) | 111.31 |
| NCAV / Share | 4.12 |
| Price / NCAV | 0.88 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -1.95 |
| Return on Equity (ROE) | -4.29 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 23.55 |
| Current Ratio | 23.55 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 120.67 |
| Assets | 123.65 |
| Liabilities | 9.37 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1.06 |
| Operating Income | -33.02 |
| Net Income | -29.36 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -25.81 |
| Cash from Investing | -0.06 |
| Cash from Financing | 128.40 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Great Point Partners Llc | 9.99 | 0.00 | |
| 13G | Nantahala Capital Management, LLC | 5.10 | ||
| 13G/A | Point72 Asset Management, L.P. | 3.00 | -47.48 | |
| 13G/A | Citadel Advisors Llc | 5.80 | ||
| 13G | Vanguard Group Inc | 6.79 | ||
| 13G | TCG Crossover GP II, LLC | 9.90 | ||
| 13G | Biotechnology Value Fund L P | 9.99 | ||
| 13G/A | Commodore Capital Lp | 9.90 | 50.34 | |
| 13G/A | BlackRock Inc. | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 10,462 | 62,309 | 16.79 | |
| 13,589 | 81,560 | 16.66 | |
| 3,906 | 284,490 | 1.37 | |
| 12,223 | 76,317 | 16.02 | |
| 10,112 | 46,576 | 21.71 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VKTX – Viking Therapeutics, Inc. | VRPX – Virpax Pharmaceuticals, Inc. |
| VSTM – Verastem, Inc. | VTVT – vTv Therapeutics Inc. |
| VXRT – Vaxart, Inc. |
Financial data and stock pages provided by
Fintel.io